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Abstract: Glioblastoma (GBM) is the most aggressive and common primary tumor of the central
nervous system. It is characterized by having an infiltrating growth and by the presence of an
excessive and aberrant vasculature. Some of the mechanisms that promote this neovascularization
are angiogenesis and the transdifferentiation of tumor cells into endothelial cells or pericytes. In
all these processes, the release of extracellular microvesicles by tumor cells plays an important
role. Tumor cell-derived extracellular microvesicles contain pro-angiogenic molecules such as VEGF,
which promote the formation of blood vessels and the recruitment of pericytes that reinforce these
structures. The present study summarizes and discusses recent data from different investigations
suggesting that Netrin-1, a highly versatile protein recently postulated as a non-canonical angiogenic
ligand, could participate in the promotion of neovascularization processes in GBM. The relevance of
determining the angiogenic signaling pathways associated with the interaction of Netrin-1 with its
receptors is posed. Furthermore, we speculate that this molecule could form part of the microvesicles
that favor abnormal tumor vasculature. Based on the studies presented, this review proposes Netrin-1
as a novel biomarker for GBM progression and vascularization.
Keywords: glioblastoma; neovascularization; Netrin-1; exosomes; transdifferentiation; pericytes
1. Introduction
Glioblastoma (GBM) is the most aggressive tumor among gliomas, defined as primary
brain cancers of a glial nature. Gliomas can be classified according to their histopatho-
logical resemblance as astrocytic tumors, oligodendrogliomas, and ependymomas. The
World Health Organization classification specifies four grades of gliomas, of which grade
IV corresponds to GBM. GBM is the most common of the primary astrocytomas and ac-
counts for more than 60% of brain tumors in adults. Despite the use of radiotherapy and
chemotherapy in patients who develop this type of tumor, they have a life expectancy that
does not exceed 15 months and less than 5% of them survive 5 years after diagnosis [1].
GBM can emerge as a primary tumor, which develops de novo without previous
clinical manifestations and affects mainly the elderly. They account for almost 90% of
all GBM cases worldwide, and they have a worse prognosis than secondary tumors,
which frequently affect younger patients. Primary GBM commonly exhibit amplification
and/or mutations of the Epidermal Growth Factor Receptor (EGFR), mutations in the tumor
suppressor genes Phosphatase and Tensin Homolog (PTEN) and TP53, complete loss of
chromosome 10, deletion of Cyclin Dependent Kinase Inhibitor 2A (CDKN2), and mutations
in the promoter of Telomerase Reverse Transcriptase (TERT). In secondary tumors, the most
frequent alterations are mutations in TP53 and the complete loss of chromosome 10 [2].
Mutations in Isocitrate Dehydrogenase (IDH) genes are more frequent in secondary GBM,
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where they reach 73% of the clinical cases, while in primary GBM, the percentage of IDH
mutated tumors is barely 3.7% [3].
In GBM, there is infiltrative growth within healthy brain tissue and excessive angio-
genesis that produces an abnormal tumor vasculature; both features are known as the main
distinguishing characteristics of these tumors [4]. In the tumor microenvironment, com-
munication between different cell groups and the promotion of some neovascularization
processes in GBM occur thanks to the presence of molecules such as Vascular Endothe-
lial Growth Factor (VEGF), basic Fibroblast Growth Factor (bFGF), Transforming Growth
Factor beta (TGF-β), and Matrix Metalloproteinases (MMPs), either as soluble isoforms or
contained in extracellular microvesicles released by tumor cells [5,6]. These signals result in
the activation of different pathways involved in cell proliferation and migration, formation
of new blood vessels, and transdifferentiation of tumor cells into endothelial cells (EC)
and pericytes, culminating into a florid and robust tumor vasculature [7,8]. In addition to
the participation of canonical angiogenic molecules, overexpression of Netrin-1, originally
discovered as a neural guidance cue, has recently been described in GBM and an important
role of this ligand in tumor angiogenesis has been proposed [9]. It has been suggested
that upon interaction with its receptors, this ligand could trigger the activation of diverse
signaling pathways that promote cell survival, proliferation, and migration. Moreover,
Netrin-1 promotes the expression of C-MYC, which could favor neovascularization in the
tumor niche [10].
The diversity of molecular alterations present in GBM has made it difficult to deter-
mine biomarkers and design effective pharmacological strategies to combat this tumor.
One of the objectives of this review is to describe the mechanisms by which glioma cells
interact with their cellular milieu to promote their aggressive growth. Moreover, we will
suggest new markers that could be altered in GBM. In particular, we will highlight the role
that Netrin-1 plays in the GBM microenvironment and suggest possible signaling pathways
through which it could be participating in the promotion of neovascularization. A greater
understanding of the molecular mechanisms underlying the onset and progression of GBM
will allow for better diagnosis and development of more efficient therapeutic strategies for
patients with this type of tumor.
2. Processes of Neovascularization in GBM
Different tumor neovascularization mechanisms have been described in GBM, such as
vascular co-option, angiogenesis, vasculogenesis, vascular mimicry, and transdifferentia-
tion of tumor cells into EC or pericytes [11]. In the process of vascular co-option, tumor cells
move towards the blood vessels found in healthy tissue adjacent to the tumor, surround
them, and move along the vessel wall [12]. This triggers events such as apoptosis, vascular
regression, and necrosis, which lead to the initiation of angiogenesis: the formation of
new blood vessels from existing ones [13]. Angiogenesis begins with the destabilization of
the basement membrane of the blood vessels by breaking the contact between pericytes
and EC. Next, the transition from an endothelial phenotype to a mesenchymal one occurs,
hence promoting the proliferative, migratory, and invasive capacities of EC, which release
different proteases that degrade the extracellular matrix and the basement membrane,
allowing the proliferation of EC which give rise to the formation of new blood vessels [14].
Vasculogenesis occurs through the recruitment of bone marrow-derived endothelial
precursor cells; also known as endothelial precursors, into the tumor tissue. Then, these
cells differentiate and form de novo blood vessels [15].
During vascular mimicry, tumor cells carry out de novo formation of perfused blood
vessels, which provide the tumor with sufficient blood and nutrients for its growth. Ac-
tually, GBM cells can transdifferentiate into EC and form functional blood vessels within
the tumor, especially in its deepest areas [16]. It has been reported that part of the vascular
endothelium in GBM has a neoplastic origin and that EC present genomic alterations
similar to the tumor cells, hence originating from GBM stem cells (GSC) [17]. Furthermore,
most of the pericytes generated in murine GBM models are derived as well from GSC
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and contribute to the formation of the tumor vasculature [18]. It has been proposed that
the GSC acquire mural cells properties and contact with the EC, providing stability to the
blood-brain-barrier (BBB). Cheng et al. demonstrated the ability of GSC to differentiate into
pericytes in vitro and in vivo by verifying the expression of specific pericyte markers such
as alpha-Smooth Muscle Actin (α-SMA), Neuron-Glial antigen 2 (NG2), CD248, and CD146 [7].
They also showed that GSC-derived pericytes represent the highest percentage of these
mural cells in GBM xenotransplants and that they are part of the new tumor vessels. These
cells possessed the most common mutations present in tumor cells, such as EGFR am-
plification and PTEN loss, confirming that they came from GSC. Besides, this research
confirmed that the elimination of tumor-derived pericytes disrupts the tumor vasculature,
which suppresses GBM growth and progression. The authors described that GSC are
recruited by tumor EC through Stromal Cell-Derived Factor 1 (SDF-1)/C-X-C Chemokine
Receptor Type 4 (CXCR4) signaling and generate pericytes mainly through activation of
the TGF-β pathway [7]. Others have shown that the process of transdifferentiation of
GSC to pericytes, which allows the development of vascular mimicry, depends on the
expression of the Vascular Endothelial Growth Factor Receptor 2 (VEGFR2/Flk-1) [18] or
the activation of the Notch signaling pathway in the tumor cells [19]. Recent data from
our group suggest that GSC-derived pericytes may be in contact with EC, acting as mural
cells and enhancing the tumor vasculature, in GBM with EGFR mutations. Alternatively,
they appear delocalized in overexpressing, but non-mutated EGFR tumors, favoring the
disruption of the BBB [20,21]. These results suggest that these different behaviors could
induce two distinct vascular phenotypes and explain the differential tumor aggressiveness
of GBM with or without EGFR mutations. Moreover, our data indicates that the EGFR
pathway controls the transdifferentiation of GSC from GBM to pericytes and that this
process is mediated by the activation of Nuclear Factor kappa B (NF-κB) [20].
3. Signals Involved in GBM Angiogenesis
Some of the most studied canonical angiogenic molecules in GBM are proteins of the
VEGF family, bFGF, Hepatocyte Growth Factor (HGF), Platelet-derived Growth Factor
(PDGF), TGF-β, MMPs, and Angiopoietins [22] (Table 1). The VEGF family includes
six secreted glycoproteins (VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental
growth factor PIGF), with VEGF-A being the best characterized. Increased expression of this
gene is positively related to the tumor grade and the poor prognosis of glioma patients [23],
both in lower-grade gliomas and GBM [21]. Notably, VEGF expression inversely correlates
with the presence of IDH mutations, which identifies the less aggressive tumors. Moreover,
among IDH wild-type GBMs, we have observed a higher expression of this and other
angiogenic factors in EGFR mutant tumors, which also progress more rapidly than their
wild-type counterparts [21].
There are different isoforms of VEGF-A, whose expression may be associated, for ex-
ample, to the formation of permeable vasculature and the decrease in pericyte coverage [24].
VEGF signaling is mediated through binding to VEGFR-1 (Flt-1), VEGFR-2, and VEGFR-3,
triggering angiogenesis, vascular permeability, and endothelial migration [25]. When VEGF
binds to its receptors present on the EC membrane, they secrete MMPs, which degrade
components of the extracellular matrix, thus promoting cell proliferation, migration, and
invasion [26]. Besides, these ligands stimulate the proliferation and activation of pericytes,
promoting their migration towards the new vessels and leading to their stabilization [27].
bFGF promotes angiogenesis by activating the proliferation and migration of EC and the
indirect activation of cell migration. The population of GSC, whose stem cell state is main-
tained by bFGF, EGF, PDGF, or TGFβ [28–31], also promotes these processes. Meanwhile,
HGF stimulates the proliferation and migration of EC and the overexpression of VEGF, in
addition to suppressing the angiogenesis inhibitor, Thrombospondin 1 (TSP-1) [32]. PDGF
directly induces EC proliferation and the formation of new blood vessels [33]. PDGF-B, a
ligand that is part of the PDGF family of proteins, stimulates the proliferation of smooth
muscle cells and pericytes towards the site where new vessels are forming and helps to
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establish a new basement membrane by binding to its PDGFR-β receptor [34]. Finally,
angiopoietins are a family of four proteins (Ang-1-Ang-4) that fulfill different roles in
angiogenesis. Ang-1 participates in the induction of new blood vessels formation and their
stabilization through reciprocal interactions between the endothelium and the surround-
ing extracellular membrane [35]. Ang-2, which is up-regulated by hypoxia, increases the
proliferation and migration of EC mediated by VEGF [36].
In addition to the molecules mentioned above, several non-classical angiogenic
molecules, belonging to the Semaphorins, Ephrins, and Netrins families, mediate this
process. All of these molecules were originally described as axon guidance molecules.
However, their overexpression and participation in both pro and anti-angiogenic processes
in cancer in general, and GBM in particular, has recently been demonstrated [37–39]. This
review will describe in greater depth the role of Netrin-1 in the neovascularization process,
the signaling pathways that could regulate its expression, and how this protein could be
participating in the tumor microenvironment of GBM.
Table 1. Participation of classical angiogenic molecules in GBM.
Molecule Function
VEGF Promotes angiogenesis, vascular permeability, and endothelial migration [25].
MMPS
Degrade the components of the extracellular matrix, promote cell proliferation, migration and
invasion [26].
Stimulate the proliferation and activation of pericytes and promote their migration towards the
newly formed vessels [27].
BFGF Promotes angiogenesis by activating EC proliferation and migration and activating cell migration.Maintains the stemness of GSC [28].
HGF Stimulates the proliferation and migration of EC and the overexpression of VEGF. Suppresses theangiogenesis inhibitor, TSP-1 [32].
PDGF
Induces the proliferation of EC and the formation of new blood vessels [33].
Stimulates the proliferation of smooth muscle cells and pericytes towards the site where the new
vessels are forming and helps to establish a new basement membrane by binding to its receptor
PDGFR-β [34].
Promotes stem-like properties of GBM cells [31].
ANG-1 Participates in the induction of the formation of new blood vessels and their stabilization throughreciprocal interactions between the endothelium and the surrounding extracellular membrane [35].
ANG-2 Increases VEGF-mediated proliferation and migration of EC [36].
SDF-1 Induces EC migration and proliferation [40].
HDGF Promotes EC migration and angiogenesis in vivo [41].
FT Induces an increase in the production of pro-angiogenic molecules such as HB-EGF through theactivation of the PAR-2 receptor in EC, triggering an increase in the formation of tubules [42].
4. Expression of Netrin-1 and Its Receptors in GBM
Both in vitro and in vivo approaches have shown that Netrin-1 promotes tumor pro-
gression, metastasis, and angiogenesis in cancer [43]. Particularly, the expression of the
Netrin-1 protein in GBM has been considered relevant in the promotion of tumor angio-
genesis [44]. Notably, participation of the Netrin-1 signaling pathway in the angiogenesis
processes in normal and injured brain has been reported [45,46].
Netrin-1 is part of the conserved family of Netrins, secreted and/or extracellular
matrix proteins, whose original role in axonal guidance has been widely described [47].
The concentration of Netrin-1 in the brain in normal conditions varies between 50 and
150 ng/mL [48]. However, in pathological conditions such as GBM, the expression of this
protein can increase between 2.1 to 4.5 times compared to normal tissues [10]. Different
cell types in the tumor microenvironment in GBM such as glial cells (astrocytes and
oligodendrocytes), microglia, infiltrating immune cells (monocytes, macrophages, and
lymphocytes), EC, and pericytes can express Netrin-1 and its receptors [47,49–58] (Table 2).
Immunohistochemical data from The Human Protein Atlas shows examples of positive
Netrin-1 staining in glioma samples, with a diffuse pattern of expression (Figure 1A).
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Table 2. Netrin-1 and its receptors expression in different cell types of the GBM microenvironment.
Cell Type Netrin-1 DCC NEO1 UNC5
Astrocytes 4 [48] 4 [50] 4 [53] -
Oligodendrocytes 4 [51] 4 [51] - -
Microglia 4 [48] - - -
Macrophages 4 [55] 4 [53] 4 [53] 4 [55]
Lymphocytes 4 [46] 4 [46] 4 [46] 4 [46]
Brain Endothelial Cells 4 [49] 4 [49] 4 [49] 4 [54]
Pericytes 4 [51] 4 [51] 4 [51] 4 [51]
In axonal guidance, the chemo-attractant effects of Netrin-1 are mediated through
Netrin-1 binding to the transmembrane molecules Deleted Colorectal Cancer (DCC) and
Neogenin 1 (NEO1), while binding of Netrin-1 to receptors of the UNC5 (UNC5 A-D) fam-
ily produces the repellents effects. Both DCC/NEO1 and UNC5 are so-called dependent
receptors (DR). In the absence of their ligand, apoptosis is promoted. Their interaction with
the ligand blocks apoptosis and stimulates cell survival, migration, and proliferation [59].
This is how DRs generate a state of cellular dependence in the presence of the specific
ligand, in this case, Netrin-1. It has been shown that this molecule has a higher affinity for
DCC/NEO1 receptor than for the UNC5 family of receptors [60] and that the effect pro-
duced by the binding of Netrin-1 to its receptors is different depending on the conformation
they adopt [61]. The attractant effects on the axon are generated by interaction of the ligand
with homodimers formed by either DCC and NEO1 receptors. The short-term repellent
effects are generated by the binding of Netrin-1 to homodimers formed by UNC5 receptors,
while the long-term effects are generated by the binding of the ligand to heterodimers
formed by receptors of the DCC and/or NEO1 and UNC5 family [10,48,62].
Netrin-1 has been proposed as a possible biomarker for different types of cancer.
Ramesh et al. demonstrated that Netrin-1 levels in the blood of patients with breast,
kidney, prostate, liver, meningioma, pituitary adenoma cancer, and GBM are increased
compared to control patients [63]. Notably, a comparative pan-cancer analysis shows
a higher transcription of this gene in gliomas compared to other cancers (Figure 1B).
Moreover, Netrin-1 expression is higher in type III and IV tumors, being related to cell
aggressiveness and tumor progression [64]. In addition to the roles of Netrin-1 described
above, the ligand has also been found to be a promoter of cellular invasiveness, which is
mediated through the activation of Notch signaling [43,65]. Ylivinkka et al. determined that
the activation of the Notch signaling pathway by Netrin-1 induces stemness properties on
GBM cells [9]. Interestingly, the same authors described a stronger expression of Netrin-1 in
areas surrounding necrosis in GBM samples, which are enriched in pro-angiogenic signals
(9). In agreement with that, the in silico analysis shows a positive correlation between the
expression of this ligand and different angiogenic-related genes such as VEGFA, ANGPT-1,
and ANGPT-2 (Figure 1C), supporting a possible role for Netrin-1 in the processes of glioma
vascularization. Furthermore, it has been described that this molecule could participate in
processes such as phagocytosis, the formation of adherent junctions, regulation of the actin
cytoskeleton, and interactions between extracellular matrix and receptors [65].




Figure 1. In silico analysis of NTN1 expression in gliomas. (A) Representative images of immuno-
histochemical staining of high-grade glioma samples using a Netrin-1 specific antibody. (B) RNA-
seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon 
per Million reads), generated by The Cancer Genome Atlas (TCGA). Data adapted under creative 
commons license from The Human Protein Atlas [66,67]. Images available from https://www.pro-
teinatlas.org/ENSG00000065320-NTN1/pathology, accessed on 12 May 2021. (C) Pearson’s correla-
tion analysis between the expression of NTN1 and VEGFA, ANGPT1, ANGPT2, using data from 
the Chinese Glioma Genome Atlas (CGGA) cohort visualized in the GlioVis data portal [68] 
(http://gliovis.bioinfo.cnio.es, accessed on 12 May 2021). The correlation coefficient (r) is shown on 
the right. Scale bar in A: 200 μm. 
Figure 1. In silico analysis of NTN1 expression in gliomas. (A) Representative images of im-
munohistochemical staining of high-grade glioma samples using a Netrin-1 specific antibody.
(B) RNA-seq data in 17 cancer types are reported as median FPKM (number Fragme ts Per Kilo-
base of exon p r Million reads), g erated by The Cancer Genome Atlas (TCGA). Data adapted
under creative commons license from The Human Protein Atlas [66,67]. Images available from
https://www.proteinatlas.org/ENSG00000065320-NTN1/pathology, accessed on 12 May 2021.
(C) Pearson’s correlation analysis between the expression of NTN1 and VEGFA, ANGPT1, ANGPT2,
using data from the Chinese Glioma Genome Atlas (CGGA) cohort visualized in the GlioVis data
portal [68] (http://gliovis.bioinfo.cnio.es, accessed on 12 May 2021). The correlation coefficient (r) is
shown on the right. Scale bar in A: 200 µm.
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Netrin-1 expression has been detected in different human GBM cell lines, such as the
commonly used U87MG or the more aggressive and invasive U373MG and U251MG cell
lines. Furthermore, it has been reported that the expression levels of Netrin-1 in human
astrocytes are lower than in U373MG and U251MG, but higher than in U87 cells [10].
On the other hand, in brain endothelial cells (BEC), the expression of Netrin-1 has been
described as moderate, while the expression of its receptor, NEO1, is high [58]. U251 cells
express the UNC5A, UNC5B, UNC5C, and UNC5D receptors, while U87 and SHG44 cells
express only the UNC5A and UNC5B receptors. NEO1, for its part, is expressed in GBM
patient’s biopsies as well as in the GBM cell lines U87MG, U373MG, and U25 [64].
Netrin-1 isoform associated with a poor prognosis has been detected in neuroblas-
toma, bronchioalveolar carcinoma, breast and colon cancer [69]. The generation of this
isoform occurs from an internal alternative promoter in the NTN1 gene, which results in
the formation of a truncated isoform of Netrin-1 that lacks the first part of the N-terminal
VI domain and is located in the nucleolus. This protein interacts with ribosomal DNA pro-
moter sequences, which stimulates ribosomal RNA synthesis, promoting cell proliferation
and tumor growth [39,69]. Such a truncated form of Netrin-1 has not been described so far
in GBM.
5. Signaling Pathways Associated with Netrin-1 Regulation
The participation of Netrin-1 in different biological processes has been widely de-
scribed. However, it is still necessary to deepen the study of the mechanisms that regulate
its expression. One of the signaling pathways involved in cancer and specifically in the
development of GBM is activated by the Sonic Hedgehog (SHH) molecule [70,71]. The
expression of components of this pathway such as SHH, PTCH1, GLI1, and GLI2 has
been demonstrated in gliomas. Moreover, activation of this signaling cascade has been
linked to proliferation, survival, self-renewal, and tumorigenicity in GBM cell lines [71]. In
another brain tumor type, medulloblastoma, we have shown that NEO1 is a direct target
of the canonical SHH signaling pathway. Milla et al. described that in these tumors, the
expression of NEO-1 is transcriptionally upregulated by the SHH effector Gli2, through its
binding to the promoter regions of the NEO1 gene [72]. Meanwhile, the Gli1 effector seems
to regulate directly the transcription of NTN1 (Falcon et al., unpublished observations). The
latter is particularly relevant since overexpression of GLI1 has been reported in GBM [72].
In addition, it has been recently described that Netrin-1 participates in the maintenance of
the stability of the BBB, being a downstream effector of the SHH pathway in other types of
CNS-related diseases [73].
Interestingly, activation of NTN1 expression in GBM could also be promoted by NF-κB,
in an indirect manner since it has been reported that this transcription factor induces the
expression of SHH in cancer [74]. In addition, NTN-1 promoter has been shown to be
directly regulated by the NF-κB pathway in colorectal cancer, which allows us to suggest
that a similar regulatory mechanism could occur in GBM (Figure 2) [75].




Figure 2. Signaling pathways that could regulate the expression of NTN1 in GBM. (A) NTN1 ex-
pression could be regulated by the canonical SHH signaling pathway, as described recently on 
medullobastoma, specifically through the transcriptional function of activator isoforms of the GLI 
zinc finger proteins (Falcon et al., unpublished observations) [72]. (B) Alternatively, the NF-κB 
pathway could modulate NTN1 expression, directly through binding to the promoter region of 
this gene, or indirectly through the regulation of SHH expression [74,75]. GLIa, GLI 1, and GLI2 
activator forms; SHH, Sonic Hedgehog protein; PTCH, Patched protein receptor; SMO, Smooth-
ened protein; IκB, inhibitor nuclear factor kappa B; NF-κB, nuclear factor kappa B; NTN1, Netrin-1 
gene. 
6. Signaling Pathways Associated with Netrin-1 and Angiogenesis 
The interaction between Netrin-1 and its DRs produces the activation of different 
signaling pathways that promote processes such as cell migration, proliferation, and an-
giogenesis. It has recently been postulated that a downstream effector of this signaling 
could be C-MYC [10]. The expression of this gene is deregulated in GBM and its activation 
has been reported to promote increased expression of VEGF, inducing angiogenesis and 
tumor growth [76–78]. This regulation could occur through the regulation of the availa-
bility of VEGF and the angiogenesis inhibitor TSP-1 [79], the binding of C-MYC to the 
VEGF promoter region [78], or the regulation of IL-1β expression [80]. Whereas the con-
nections of C-MYC with angiogenesis is well stablished, the activation of this transcription 
factor in response to Netrin-1 signaling remains to be fully characterized (Figure 2). Recent 
results obtained in our laboratory indicate that interaction between Netrin-1 and NEO1 
triggers the activation of Integrin β1 (ITGB1) through the key integrin signaling compo-
nent Focal Adhesion Kinase (FAK), which promotes cell migration and, consequently, me-
tastasis in neuroblastoma [81]. Upon Netrin-1 binding to NEO1, FAK undergoes auto-
phosphorylation at tyrosine residue 397 to induce intercellular signaling. Our findings are 
in line with previous work illustrating that DCC/NEO1 can coopt FAK to induce down-
stream signaling [82]. Of note, it has been described that the activation of ITGB1 through 
FAK and the regulation of MAPK/SRC pathways, in addition to promoting cell prolifera-
tion, induces the expression of C-MYC in tumor cells [83]. Moreover, a series of papers 
have indicated that netrins can bind directly to the α6β4 or α3ITGB1 integrin complex and 
cause integrin signaling. As such, evidence for cross talk—and potentially cooperative 
signaling—by integrins and classical Netrin-1 receptors in the context of GBM cannot be 
discarded. Hence, it is possible to suggest that the activation of the signaling complex 
Figure 2. Signaling pathways that could regulate the expression of NTN1 in GBM. (A) NTN1 expression could be regulated
by the canonical SHH signaling pathway, as described recently on medullobastoma, specifically through the transcriptional
function of activator isoforms of the GLI zinc finger proteins (Falcon et al., unpublished observations) [72]. (B) Alternatively,
the NF-κB pathway could modulate NTN1 expression, directly through binding to the promoter region of this gene, or
indirectly through the regulation of SHH expression [74,75]. GLIa, GLI 1, and GLI2 activator forms; SHH, Sonic Hedgehog
protein; PTCH, Patched protein receptor; SMO, Smoothe ed protein; IκB, inhibitor nuclear factor kappa B; NF-κB, nuclear
factor kappa B; NTN1, Netrin-1 gene.
6. Signaling Pathways Associated with Netrin-1 and Angiogenesis
The interaction between Netrin-1 and its DRs produces the activation of different
signaling pathways that promote processes such as cell migration, proliferation, and an-
giogenesis. It has recently been postulated that a downstream effector of this signaling
could be C-MYC [10]. The expression of this gene is deregulated in GBM and its activa-
tion has been reported to promote increased expression of VEGF, inducing angiogenesis
and tumor growth [76–78]. This regulation could occur through the regulation of the
availability of VEGF and the angiogenesis in ibitor TSP-1 [79], the binding of C-MYC
to the VEGF promoter region [78], or the regulation of IL-1β expression [80]. Whereas
the co nections of C-MYC with angiogenesis is well stablished, the activation of this
transcription factor in response to Netrin-1 sign ling remains to be fully characterized
(Figure 2). Recent results obtained in our laboratory ind cate that interaction between
Netrin-1 and NEO1 triggers t e activation of Integrin β1 (ITGB1) through the key integrin
signaling compo ent Focal Ad esion Kinase (FAK), which promotes cell migration and,
consequently, metastas s in neuroblasto a [81]. Upon Netrin-1 binding to NEO1, FAK
undergoes auto-phosphorylation at tyrosine residue 397 to induce intercellular signaling.
Our findings are in line with previous work illustrating that DCC/NEO1 can coopt FAK
to induce down eam signaling [82]. f note, it has been described that the activation of
ITGB1 through FAK and the regulation of MAPK/SRC pathways, in addition to promoting
cell pr liferation, induces the expression of C-MYC in tumor cells [83]. Moreover, a series
of pa ers have indicated that netrins can bind directly to the α6β4 or α3ITGB1 integrin
complex and cause integrin signaling. As such, evidence for cross talk—and potentially
cooperative signaling—by integrins and classical Netrin-1 receptors in the context of GBM
cannot be discarded. Hence, it is possible to suggest that the activation of the signaling com-
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plex Netrin-1/NEO-1 could lead to the activation of ITGB1 through FAK and subsequent
activation of C-MYC in GBM, resulting in aberrant vascularization.
Interestingly, Huyge et al. described recently that the expression of Netrin-1 and
its receptors NEO1 and UNC5B participate in the promotion of pluripotency in Mouse
Embronic Stem Cells (mESCs) through co-regulation of the Wnt and MAPK signaling
pathways. According to their results, increased expression of Netrin-1 causes a greater acti-
vation of the Wnt pathway through FAK, which promotes the phosphorylation of Gsk3α/β
and the stabilization of β-catenin, processes in which the participation of receptors NEO1
and UNC5B is required. Moreover, the promotion of pluripotency in mESCs due to the
expression of Netrin-1 is mediated in part by the induction of C-MYC activation and ex-
pression [84]. These results suggest that oncogenic activation of C-MYC could be mediated
by the regulation of the Wnt/β-catenin signaling pathway, which is also activated in GBM,
promoting proliferation processes, apoptosis inhibition, and cell invasion [85].
Finally, it has been described that the expression of C-MYC in GBM can also be induced
through the interaction of Netrin-1 and the UNC5A receptor, and that this interaction could
promote the growth of gliomas through the induction of C-MYC, mediated by activation
of the NF-κB pathway [10]. As mentioned, NF-κB signaling is aberrantly activated in
GBM and has been implicated in processes such as stem cell maintenance, stimulation of
cell invasion, cell migration, angiogenesis, and resistance to radiation therapy [86]. Such
signaling has been shown to regulate C-MYC expression in GBM through phosphorylation
of Ser536 in the p65 subunit of NF-κB [10]. This subunit is part of the five molecules that
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7. Pro-Angiogenic Molecules Contained in Exosomes Derived from GBM Cells
The promotion of angiogenesis in the tumor microenvironment can also be carried
out through the release of molecules contained in exosomes. Exosomes are microvesicles
released by cells under both ormal and pathological physiological conditions. They have
a diameter of less than 100 nm, have a lipid bilayer and contain different molecules such
as proteins, lipids, DNA, RNA, amo g others [88]. Different investigations reveal the
presence of growth fact rs, proteases, miRNAs, and long non-coding RNAs in exosomes
released by GBM cells [5,6,8,9,89–91]. All these molecules can promote angiogenesis in
GBM through increased proliferative, migrato y, invasive, and tubule-formation capacities
of EC (F gure 4) [6,8,9,91–93]. Noteworthy, many o the ngiogenic molecules released by
GSC are found within exosomes and partic pate in the promotion of neovascularization
processes [89,94–96].
Int. J. Mol. Sci. 2021, 22, 8248 11 of 17




Figure 4. Schematic of possible participation of GBM cell-derived exosomes in promoting angio-
genesis in the tumor niche. The figure depicts the possible content of exosomes derived from GSC 
and/or those derived from GBM tumor cells (growth factors, proteins, proteases, and ncRNAs) 
[5,6,8,9,89–91]. Besides, the uptake of these microvesicles by EC in the tumor vasculature, may 
promote the increase in the formation of new blood vessels through the promotion of cell prolifer-
ation, migration, and invasiveness [6,8,9,91–93]. 
Although the presence of Netrin-1 in microvesicles derived from GBM tumor cells 
has not been reported to date, other molecules with similar functions have been found in 
exosomes. Saman et al. demonstrated that the overexpression of TAU in neuroblastoma 
cells promotes the enrichment of molecules associated with axonal guidance, such as ne-
trins in exosomes released by those cells [98]. As Netrin-1 is also an axonal guidance pro-
tein and both the expression of TAU and Netrin-1 have been reported in GBM, it is possi-
ble to think that the expression of TAU could promote the enrichment of Netrin-1 in exo-
somes released by those cells. In GBM, the presence of proteins belonging to the Sema-
phorin family, axonal guidance proteins as well and non-canonical angiogenic proteins 
have been reported within exosomes [99]. Moreover, Semaphorin 7A has been reported 
to be exposed on the surface of exosomes and binds to GSC through ITGB1. This interac-
tion activates FAK within GSC, promoting their mobility [100]. 
The angiogenic molecules released by GBM cells can also promote other neovascu-
larization processes in GBM, such as the process of transdifferentiation of tumor cells to 
pericytes. Previously, in this review, the participation of GSC in the process of transdif-
ferentiation of pericytes was highlighted, which through pro-angiogenic molecules such 
as VEGF and TGF-β promote the appearance of pericytes derived from GSC [101]. We 
could hypothesize that the secretion of exosomes containing Netrin-1 might participate in 
the promotion of the process of transdifferentiation from tumor cells to pericytes through 
its interaction with the UNC5A receptor, which would trigger the activation of NF-κB 
[102] and the tumor-to-pericyte transformation [20]. 
8. Projections 
Data presented in this review strongly suggested a possible role of Netrin-1 in the 
neovascularization processes in GBM. As discussed earlier, the study of how GBM se-
cretes Netrin-1 is primordial. In particular, it is required to determine if this protein is 
Figure 4. Schematic of possible participation of GBM cell-derived exosomes in promoting angiogenesis in the tumor niche.
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factors, proteins, proteases, and ncRNAs) [5,6,8,9,89–91]. Besides, the uptake of these microvesicles by EC in the tumor
vasculature, may promote the increase in the formation of new blood vessels through the promotion of cell proliferation,
migration, nd invasiveness [6,8,9,91–93].
As we have highlighted, tumor angiogenesis in GBM is also promoted by the expres-
sion of non-canonical angiogenic molecules such as Netrin-1. In GBM, overexpression of
this protein has been identified both in cell lines and in tumor tissue and its participation in
promoting tumor angiogenesis through increased cell proliferation and tubule formation
has been reported. Classic angiogenic molecules such as VEGF-A have been identified
in the conditioned medium of GBM cells [96]. However, there is still no information that
reports the presence of Netrin-1 in conditioned medium or exosomes of GBM cells, and in
particular, in GSC. Recently, the presence of axonal guidance molecules within exosomes
released by tumor cells has been described [97], which would suggest that Netrin-1 could
be released as well as contained within these microvesicles.
Although the presence of Netrin-1 in microvesicles derived from GBM tumor cells
has not been reported to date, other molecules with similar functions have been found in
exosomes. Saman et al. demonstrated that the overexpression of TAU in neuroblastoma
cells promotes the enrichment of molecules associated with axonal guidance, such as netrins
in exosomes released by those cells [98]. As Netrin-1 is also an axonal guidance protein
and both the expression of TAU and Netrin-1 have been reported in GBM, it is possible to
think that the expression of TAU could promote the enrichment of Netrin-1 in exosomes
released by those cells. In GBM, the presence of proteins belonging to the Semaphorin
family, axonal guidance proteins as well and non-canonical angiogenic proteins have been
reported within exosomes [99]. Moreover, Semaphorin 7A has been reported to be exposed
on the surface of exosomes and binds to GSC through ITGB1. This interaction activates
FAK within GSC, promoting their mobility [100].
The angiogenic molecules released by GBM cells can also promote other neovascu-
larization processes in GBM, such as the process of transdifferentiation of tumor cells to
pericytes. Previously, in this review, the participation of GSC in the process of transdiffer-
entiation of pericytes was highlight , which t rough pr -angiogenic molecules such as
VEGF and TGF-β romote the appearance of pericytes derived from GSC [101]. We could
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hypothesize that the secretion of exosomes containing Netrin-1 might participate in the
promotion of the process of transdifferentiation from tumor cells to pericytes through its
interaction with the UNC5A receptor, which would trigger the activation of NF-κB [69]
and the tumor-to-pericyte transformation [20].
8. Projections
Data presented in this review strongly suggested a possible role of Netrin-1 in the
neovascularization processes in GBM. As discussed earlier, the study of how GBM secretes
Netrin-1 is primordial. In particular, it is required to determine if this protein is present
in a soluble way in the conditioned medium of the tumor cells or within the microvesi-
cles released by them. Furthermore, it would be necessary to determine if the Netrin-1
concentration in exosomes derived from GBM cells is higher than in exosomes released
by other cell types present in the tumor microenvironment, such as astrocytes. The use of
exosomes to find new cancer biomarkers is of great importance in the clinical area, because
the methods used now, such as the detection of antigens in blood, are mostly for more
than one type of cancer. In addition, techniques such as the blood test in stool samples in
colorectal cancer and the endoscopic tests carried out for the diagnosis of gastric and colon
cancer are highly invasive for patients, so the use of more specific and sensitive techniques,
such as detection of markers contained in exosomes are necessary for cancer detection [102].
In GBM, currently, the diagnostic methods are based on neuroimaging techniques and
brain biopsies, the latter being an invasive method for the patient. The detection of GBM
biomarkers contained in exosomes from blood or urine samples would be a very useful
non-invasive alternative [103].
In this way, a high concentration of Netrin-1 could be related to the presence of GBM
and not to a normal condition. Furthermore, it would be interesting to determine if the
angiogenic effect of Netrin-1 varies according to the way it is released. In addition to
knowing the role of Netrin-1 in the angiogenesis process in GBM, it would be useful to
study its participation in some of the neovascularization processes described above. By
employing a co-culture of BEC cells with GSC, the ligands participation in the process
of transdifferentiation of GSC to pericytes could be carried out. Specifically, the GSC’s
Netrin-1 expression could be decreased through loss of function approaches, which would
then be co-cultured with BEC cells. This would allow to determine if their ability to
transdifferentiate into pericytes decreases and/or if their capacity to attach to ECs is
affected. These studies could provide information on the participation of Netrin-1 in
tumor angiogenesis processes, its role in the process of transdifferentiation of tumor cells
to pericytes.
Since the presence of Netrin-1 has been detected in samples of cerebrospinal fluid from
patients with brain tumors [104], it is possible to suggest this protein as a useful biomarker
to determine the presence of GBM. Moreover, the tumor state could be determined because
it has been described that overexpression of Netrin-1 is related to type III and IV gliomas.
This would allow the diagnosis of patients with GBM to be much more accurate. Moreover,
it would facilitate monitoring those patients who have already received treatment and to
know if it has been effective or if there is a recurrence of the disease. Recently, a clinical trial
has started the first phase I trial in humans aimed at evaluating the safety, pharmacokinetics,
and clinical activity of a humanized monoclonal antibody targeting Netrin-1 (NP137) in
patients with advanced/metastatic solid tumors. If the results of this clinical trial were
positive, the use of this antibody could be a new option treatment possibility in GBM
patients (ClinicalTrials.gov identifier (NCT number): NCT02977195).
9. Conclusions
The secretion of angiogenic molecules from tumor cells into the tumor microenvi-
ronment facilitates the development of neovascularization in GBM. This review describes
the participation of classical angiogenic molecules, as well as Netrin-1, a non-canonical
angiogenic molecule, in these processes. Although the role that Netrin-1 plays in GBM
Int. J. Mol. Sci. 2021, 22, 8248 13 of 17
has been described, it is necessary to study the way it is secreted by tumor cells and the
possible signaling pathways through which it could promote neovascularization in GBM.
However, in light of the data presented in this review, it is possible to suggest Netrin-1 as a
possible biomarker for GBM. Due to the relationship between its expression and tumor
progression, it is possible to speculate that by decreasing its expression, a decrease tumor
growth or tumorigenicity of GBM cells could be achieved. The latter could contribute to
improve the efficiency of current treatments and, therefore, the survival of patients.
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